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GENERAL INTRODUCTION 
Pseudorabies (PR) has been described as economically the most significant 
viral disease of swine.31 This dubious honor has been attained in the United 
States partially as a result of the eradication of hog cholera. The success of the 
hog cholera control and eradication program, coupled with the availability of 
diagnostic tools deemed adequate to detect PR infected swine, encouraged 
swine industry leaders to seek federal and state regulatory assistance in an 
effort to eradicate pseudorabies from domestic swine in the United States. A 
national pseudorabies eradication program involving the combined efforts of 
the swine industry, federal and state regulatory agencies, and state and federal 
veterinary diagnostic laboratories was officially initiated January 1, 1989.4 The 
stated goal of the program is the complete eradication of this disease by 1999. 
This ambitious undertaking relies almost exclusively on the serological 
testing of large numbers of swine in order to determine herd and animal 
infection status and to monitor the effectiveness of eradication efforts. 
The advent of the national eradication program has had a clear impact on 
the demands placed on state veterinary diagnostic laboratories. That impact is 
most evident in the large swine producing states in the northern midwestern 
section of the country. Iowa is the leading swine producing state in the 
country, with over 35,000 herds and 1.6 million breeding swine in 1990.115 
The Veterinary Diagnostic Laboratory at Iowa State University performed 
nearly 275,000 PRV serology tests in 1990, and the current trend is clearly 
upward; over 206,000 PRV serology tests were performed in just the first six 
months of 1991. Nine different serological assays for the detection of 
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antibodies against pseudorabies virus (PRV) were used at some time during 
the last year in this laboratory. These serological assays fall into two main 
categories: screening assays that detect the humeral immune response 
induced either by vaccination or infection, and differential assays that detect 
the response to infection, but not to vaccination with a companion gene-
deleted vaccine. The screening assays include the standard serum virus 
neutralization (SVN) test,41 a commercial latex agglutination test (LAT),a and 
two commercial enzyme-linked immunosorbent assays (ELISAs).b,c Four 
commercial differential PRV ELISAsd ,e ,f ,g are in use in this laboratory, and 
another was discontinued as a result of performance problems.h The 
availability of the differential diagnostic assays as companions to gene-deleted 
vaccines has caused the percentage of screening tests performed as compared 
with the total number of tests performed to decrease. However, the actual 
number of screening tests performed at this laboratory continues to increase 
due to the dramatic increase in the overall demand for PRV serological 
testing. Over one half of the total number of PRV tests performed for the first 
six months of 1991 (nearly 108,000 tests) consisted of screening assays applied 
a Pseudorabies Virus Antibody Test Kit - Latex Agglutination, Viral Antigens Inc., 
Memphis, TE. 
b HerdChek®: Anti-PRV (S), IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, 
ME. 
c DiaSystems® CELISA PRVTM, TechAmerica™ Diagnostics, Omaha, Nebraska. 
d HerdChek®: Anti-PRV-gpX, IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, 
ME. 
e HerdChek®: Anti-PRV-gI, IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, 
Maine. 
f DiaSystems® CELISA OmniMark™ PRV, TechAmerica™ Diagnostics, Omaha, 
Nebraska. 
g ClinEase-PRV®, SmithKline Beecham, Lincoln, Nebraska. 
h Tolvid® Diagnostic, Agdia, Inc., Elkhart, Indiana. 
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to sera from nonvaccinated swine. A need has arisen for the development of 
a screening assay for PRV that can process large numbers of swine sera 
quickly, and also maintain or improve the high levels of specificity and 
sensitivity achieved by currently available test procedures.7,101 
A particle concentration fluorescence immunoassay45 (PCFIA) has been 
developed for the detection of antibodies to pseudorabies virus (PRV) in 
swine sera. The PCFIA is an automated procedure that involves the use of a 
computer-linked multipurpose instrument, the IDE.XX™ Screen Machine.i 
Manual pipetting of the sera and sample diluent is required, but all 
subsequent steps are performed automatically. 
The PCFIA for pseudorabies virus is a competitive immunoassay using 
polystyrene particles coated with partially purified PRV antigen. The 
conjugate is a fluorophore-labelled monoclonal antibody to PRV. The 
amount of particle-bound fluorescence is measured as photon counts by 
front-surface fluorimetry. The PCFIA allows the automated testing of large 
numbers of samples in a short period of time. Once samples have been 
pipetted, a 10 plate batch run (944 samples) is completed in 1 hr 45 min. To 
maximize throughput, a final batch may be set up to run unattended 
overnight. 
The goal in the development of the PRV PCFIA was to create a screening 
assay that performed comparably to conventional PRV serology procedures 
commonly used in veterinary diagnostic laboratories, but was better suited for 
iIDEXX Laboratories, Inc., One IDEXX Dri ve, Westbrook, Maine. 
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the testing of large numbers of sera. This thesis describes a project to evaluate 
the specificity, sensitivity and practicality of the PCFIA for PRV. 
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LITERATURE REVIEW 
Introduction 
Pseudorabies is a disease of significant economic importance in most 
swine producing areas of the world.31,34 Those countries without 
pseudorabies include Australia, which has managed to avoid importation of 
the disease, and Great Britain, which has essentially eradicated PRV by a 
control and eradication program based on slaughter with compensation and 
salvage of marketable pigs for human consumption.92 Pseudorabies was first 
described in the scientific literature in 1902 by a Hungarian, Aladar Aujeszky,5 
as a fatal infectious disease in cattle, dogs, and cats, and the disease is 
commonly referred to as Aujeszky's disease in Europe. In 1934, Shope103 
demonstrated antibodies against pseudorabies in swine from the midwestern 
United States. However, the presence of PRV infections in cattle in the 
United States as early as 1813 has been inferred from references in the popular 
press to a condition called "mad itch".39 
The overall economic impact of PR to the U. S. swine industry is difficult 
to calculate. Estimates range from more than 21 million dollars per year (in 
1987)38 to from 30 to 72 million dollars annually.SI The cost of PR outbreaks 
has been estimated at approximately 10,000 dollars per year per outbreak.51 A 
significant portion of the overall cost of PR to the swine industry may be 
attributed to the regulatory and diagnostic testing requirements due to its 
status as a controlled disease in swine. 
The United States swine population in 1990 consisted of 276,585 herds 
with 6,922,100 breeding swine.115 The national average prevalence of PR in 
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U.S. swine herds on December 31, 1990 was 2.4%.4 The disproportionate 
impact of PR on the states with higher concentrations of swine is reflected in 
the 37.2% prevalence rate of infected herds in Iowa in 199Q.115 
Pseudorabies virus has a wide host range, including cattle,47,111 
sheep,111,116 goats,34 dogs,28 and cats28 among the domestic animals, and is 
nearly always fatal in these species.34 However, the pig is considered to be the 
reservoir host for PRV.34,81 Clinical symptoms in the pig range from 
unapparent to death of the affected pig.34 The severity of the disease is 
usually age-related; the younger the pig, the more severe the symptoms and 
the higher the mortality rate.10,21,34,81,125 Pseudorabies clinical signs may 
include fever, anorexia, vomiting, depression, ataxia, tremors, paralysis, 
convulsions, and even sudden death.21,34 Respiratory involvement is 
generally present, and may be the primary response in older pigs.21,80 Adult 
swine exhibit varying degrees of fever, sneezing, coughing, and anorexia, and 
the mortality rate among this age group may reach 2% in a susceptible herd. 
However, the greatest risk in infections of adult swine is to the pregnant sow. 
PRV will cross the placental barrier and infect th~ embryo or fetus, resulting 
in embryonic resorption, fetal abortion, mummification, or stillborn or weak 
infected newborn piglets, depending on the stage of pregnancy at the time of 
infection and other factors relating to the severity of the virus 
challenge.23,34,55,125 Other factors affecting the course and severity of the 
clinical disease due to infection with PRV include the virulence of the virus 
strain, the virus dose and route of infection, host species, level of stress, and 
the immune status of the host.10,125 
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The natural means of transmission of PRV in swine occurs primarily by 
exposure to infectious upper respiratory secretions via the oral and nasal 
routes.21,34,65,88,125 Initial virus replication occurs in the nasopharyngeal 
region and the upper respiratory tract.34,123,125 Invasion of the central 
nervous system and, presumably, centrifugal spread of the virus occurs by the 
neural pathways, probably via the axoplasm.34,98,99,123 Viremia occurs, 
although it is of low titer and intermittent.34 PRV infects peripheral blood 
lymphocytes, and can be distributed to all parts of the body in this 
manner. 34, 125 
Pseudorabies virus can persist in a latent state in pigs that have recovered 
from the disease.22,97,125 Latency can occur in the presence of maternal 
antibodies,71,118 and in pigs vaccinated with either killed or modified live 
vaccines.75,102 Schoenbaum et al. reported that, although vaccination did not 
reduce the rate of occurrence of latent infections, shedding of the virus 
following reactivation was reduced in vaccinated pigs.102 In contrast, van 
Oirschot and Gielkens reported that intranasal vaccination did lessen the 
ability of virulent virus to cause latent infections, although it did not totally 
prevent it.119 The detection of latently infected domestic and feral swine 
remains a serious impediment to the success of the eradication of PR in the 
swine population.51,75 Pigs that maintain a humoral immune response can 
be detected by a sufficiently sensitive serological assay, but detection of a 
serologically negative latently infected pig remains a difficult task. A number 
of methods have been used to detect PRV in latently infected pigs. 
Reactivation of latent PRV can be stimulated by the use of 
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immunosuppressants such as dexamethasone71,75 or prednisolone.125 Tissue 
explant and co-cultivation virus isolation techniques have successfully 
identified the presence of latent virus in various tissues, especially neural 
tissues such as the trigeminal ganglion.97,118,125 Molecular DNA 
hybridization techniques have been shown to be more sensitive than cell 
culture methods in the detection of pigs latently infected with PRV)B,35,64,96 
Properties of Pseudorabies Virus 
Pseudorabies (Aujeszky's disease) virus has been formally named Suid 
herpesvirus 1.61 PRV is a member of the family Herpesviridae, and is further 
assigned to the subfamily Alphaherpesvirinae, along with herpes simplex 
virus in man.12,77 The PRV virion is approximately 180 run in diameter, and 
is made of the four typical herpesvirus architectural elements: a central core 
containing the DNA and bound fibrillar protein; an icosadeltahedral capsid 
with 162 protein capsomers; a globular tegument surrounding the capsid; and 
a double or triple lipid envelope containing glycoproteins and 
lipoproteins.12,95, 125 
The PRV genome consists of a linear, double stranded DNA with a 
molecular weight of approximately 90 X 106 daltons and with a size of 
approximately 145 kilobase pairs.125 The DNA molecule can be visualized as 
consisting of four functional regions. Starting at the left (5') end of the 
molecule, a long unique (UL) segment is followed by an internal repeat (IR) 
sequence, a short unique (Us) sequence, and, finally, by the terminal repeat 
(TR) sequence of base pairs.13,125 
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Seven known glycoproteins are coded for by the PRV genome.118 
Glycoproteins gII,73 gIIT,91 and gH120 are encoded by genes in the UL segment. 
Glycoproteins gJ,125 gX,89 gpSo,121 and gp6372 are encoded by genes located in 
the Us segment of the genome. Table 1118,125 summarizes selected properties 
of six of the PRV glycoproteins (gH was only recently identified and very little 
is known about it). All of the glycoproteins except gX are structural 
components of the viral envelope. In contrast, gX is synthesized in large 
quantities in infected cells and excreted into the supernatant of infected cell 
cultures.11 The function of gX is unknown. Only gII and gpSO are essential to 
viral replication. The virulence of PRV is multigenically controlled.118 At 
least three glycoproteins, gI, gp63, and gIIl, may play a role in the release of the 
virus from infected cells.118,125 Glycoprotein gII may be important in the 
process of membrane fusion and penetration of the infected celL 125 
Adsorption of the virus to the target cell may be mediated by gill and gpSQ.125 
Glycoproteins gIII and gpSO serve as major immunogens for PRV, with a 
possible lesser role for gl and gII.125 
Thyrnidine kinase (TK) is a nonglycosylated protein encoded by a gene on 
the UL segment of the genome. The TK gene is an important virulence factor 
for PRV that enables the virus to replicate in neural tissue, which is deficient 
in thymidine kinase.51 The establishment of a latent infection in neural 
tissue is believed to be facilitated by the TK enzyme.112 
Pseudorabies Virus Vaccines 
Vaccination of domestic animals for pseudorabies has been practiced for 
many years; the earliest reference to vaccination found as part of this 
Table 1. Properties of the PRV glycoproteins125,120 
Property gI gII gIII gX gpSO gp63 
Functions release penetration? release ? adsorption? release 
adsorption 
temp. stability 
MW (mature) 130 kd 155kd 90kd 95-99 kd 50-60 kd 63kd 
Gene lo ca ti on Usa ULb UL Us Us Us 
Structural gp + + + + + 
Essential gp + + 
Virulence + ? + ? + 
...... 
Immunogen 0 
Neutralizing in vivo ± ± + + 
Induce CTLC in mice ? + ? 
Protective (vaccine) ? ? + + ? 
a Us = short unique genome segment 
b UL= long unique genome segment 
c CTL = cytotoxic T cells 
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literature review was published in 1936, and was titled "La vaccination des 
animaux contre la maladie d'Aujeszky est-elle possible?"90 The same 
question may be asked today, but rephrased in the context of whether it is 
possible to eradicate PR from the swine population in the face of the 
widespread use of vaccination as an integral part of the eradication effort. 
Currently licensed vaccines in the United States are listed in Table 2, along 
with information about the source of the vaccine strain, gene deletions, and 
the availability of companion serological diagnostic tests. 
Commercially available vaccines for PR are either modified live virus 
(ML V) or killed virus preparations. The use of ML V vaccines may be 
preferable in certain situations. MLV vaccines may stimulate longer lasting 
antibody production than killed products, and may induce an immune 
response in vaccinated pigs that mimics natural infection better than killed 
vaccines.76 In addition, ML V vaccines may be administered by the intranasal 
route,24,76,99,117,119,l23 which may be a superior route of vaccination because 
it induces local immunity at the normal portal of virus entry,76 and may be 
superior to intramuscular vaccination in overcoming passive maternal 
antibody interference with the active immune response to vaccination.125 
Potential disadvantages to the use of MLV vaccines include the risk of 
reversion to greater virulence in the host animal,67,70,81,84 although 
reversion has not proved to be a problem in actual practice.25,76 Infectious 
contaminants are a greater risk in live vaccines; adventitious viruses found 
in various vaccines have included avian leukosis and other retroviruses, 
bovine viral diarrhea virus, porcine parvovirus, and cytomegalovirus.76 
Table 2. Pseudorabies vaccines and companion differential diagnostic tests licensed in the United States 
Vaccine Manufacturer PRV Strain Deletion TI< Differential Test 
Bio-Ceutic (MLV) Boehringer I Bartha gl, gp63 + HerdChek:Anti-PRV-gpl 
Ingelheirn (IDE:XX) 
OmniMark (ML V) TechArnerica PRY (dlg92dltk) gill CELISA OmniMark PRY 
(NovaGene, Inc.) (from BUI<) 
Pseudo-Cell (ML V) Grand Labs Field None + None 
PR-Vac (MLV) SmithKline Norden gI + ClinEase (SKB) 
Beecham (SKB) (from BUI<) HerdChek:Anti-PRV-gl 
PR-Vac (killed) SmithKline Norden gI ClinEase (SKB) 
..... 
+ N 
Beecham (from BUI<) HerdChek:Anti-PRV-gl 
PRV / Marker (ML V) SyntroVet from Iowa S-62 x HerdChek:Anti-PRV-gpX 
(IDEXX) 
PRV / Marker Gold SyntroVet from Iowa S-62 gX, gl HerdChek:Anti-PRV-gpX 
(MLV) HerdChek:Anti-PRV-gl 
PRV-mune (killed) Oxford Field None + None 
Laboratories 
Su vaxyn PRV (killed) Solvay Field None + None 
Tolvid (MLV) Upjohn PRY ~tl<dgX-1 gX PR gX-Tolvid 
(from Rice) (Agdia) 
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Another possible risk of ML V vaccines is the excretion of vaccinal virus to 
animals in close proximity to the vaccinated pig,25,67,81 but post-vaccinal viral 
excretion has been reported not to occur for a number of vaccine 
strains.25,44,66 Another potential risk of the use of MLV vaccines is the 
possibility that a vaccine strain replicating in the host might genetically 
recombine with a virulent field strain.40,48 This possibility could have an 
impact on the current vaccination strategy relied upon for eradication and 
control programs, as discussed below. This strategy relies on the use of 
vaccines with known genetic deletions for specific immunogenic 
glycoproteins. Companion differential serology tests that detect the humoral 
response to the missing glycoprotein can then differentiate between infection 
and vaccination responses. Genetic recombination of a gene-deleted vaccine 
strain with a virulent field strain of PRV could result in either the restoration 
of the missing gene product in the vaccine strain, or in the deletion of the 
marker gene in the virulent strain. In the former case, the pig would be 
detected by the differential assay because antibodies against the diagnostic 
glycoprotein would be present. In the latter case, the antibody response to a 
gene-deleted virulent strain would not be detected by the differential test. 
However, this would be of practical concern only if the gene-deleted virulent 
strain were to become the sole or predominant strain presented to the 
immune system, an occurrence that has not been reported in the literature, 
and would seem an unlikely event. Because gene deletions generally 
decrease the virulence of the virus, the gene deleted strain would probably 
not compete well against the nondeleted strain in the host animal. 
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Killed virus vaccines avoid nearly all of the potential problems associated 
with the use of ML V vaccines, providing inactivation is complete.67,70,76 
However, killed PRV vaccines have been reported to confer less protection 
than ML V vaccines,25,66,67 although equal efficacy has also been reported.2,25 
Killed vaccines must be given parenterally, and, due to the lack of viral 
replication, there is generally a lower antibody titer, a shorter duration of the 
immune response, and less local immunity at the sites of viral entry into the 
pig.70,76 Two doses of killed PRV vaccines are generally necessary to confer 
adequate protection, while a single MLV dose is usually considered 
adequa te?0,76 
Subunit vaccines constitute a third class of vaccines that have been 
evaluated experimentally, but are not available commercially. Pseudorabies 
virus subunit vaccines have been prepared from non-ionic detergent extracts 
containing mostly glycoproteins from the viral envelope.59,85,86,93 Platt 
developed a subunit vaccine by purifying a Triton-X-100 crude viral extract 
with the use of lectin affinity chromatography.86 A 98 kd antigen found in 
high concentration in the maintenance media of infected cell cultures, but 
not found in the lectin purified vaccine preparation, was designated the 
subunit diagnostic antigen (SUDA).87 The SUDA was used to create an 
indirect ELISA that could distinguish between antibody responses due to 
infection and vaccination.87 This diagnostic antigen was probably the same as 
gX, 115 so this test may be considered a precursor of the present day anti-gX 
differential ELISAs.20,60 
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Many of the early PR vaccines were attenuated live virus vaccines 
developed by the serial passaging of field strains of virus in cell cultures or in 
non-porcine hosts.9,16,105,118,125 This was true for the Bartha vaccine virus 
strain,8 which was isolated from a pig, then attenuated by serial passages in 
porcine kidney cell cultures, followed by adaptation to chicken embryo 
fibroblasts (CEF). Similarly, serial passages of a field isolate of PRV in the 
chorioallantoic membrane of embryonated chicken eggs, followed by passages 
in CEF cultures, led to the creation of the attenuated BUK (Bucharest) virus 
strain.127 Other attenuated vaccine strains were derived from the BUK strain, 
including the Norden vaccine strain 113 and the genetically engineered 
vaccine strains created by Kit and others.53,54 The attenuation of the BUK and 
Bartha-derived "conventional" vaccine strains was due to genetic mutations 
induced by the serial passaging in the heterologous cell or tissue 
cultures.51,118 These mutations are still being elucidated, but share in 
common deletions in the Us segment of the PRV genome that code for the gI 
and gp63 glycoproteins.51,118,125 These deletions may be complete or only 
partial. Thus, most vaccine strains derived from both the BUK and Bartha 
strains do not produce gl, but the BUK clone selected by Kit to produce his 
genetically engineered vaccine strains happened to be gI positive.51 Similarly, 
most Bartha derived strains do not produce any gp63, while most BUK 
derived strains produce an altered (truncated) gp63.118,125 
As mentioned previously, the current strategy for the integration of 
vaccination into a control or eradication program for PR involves the use of 
deletion mutant vaccine virus strains coupled with companion diagnostic 
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serology assays that can differentiate between the humoral immune response 
due to vaccination and infection.76,118 European countries, especially those 
countries with high densities of swine populations, such as the Netherlands 
and Germany, have moved towards adoption of gl-deleted vaccines as the 
only approved vaccine type.118 The situation in the United States has been 
less regulated. As a result, several types of gene deleted vaccines with their 
companion glycoprotein specific antibody assays are currently commercially 
available. Table 2 lists the licensed PR vaccines currently available in the U.S. 
Vaccines that do not express the gl, gX or gill glycoproteins are available in 
this country, although the gl and gX deleted vaccines predominate. These 
vaccines must meet additional minimal standards above and beyond the 
usual requirements for efficacy and safety. These additional requirements 
relate to the need for the glycoprotein specific antibody assay to be able to 
detect infected animals reliably, and differentiate them from vaccinated 
animals. The deleted glycoprotein used as the differentiating diagnostic 
antigen must be present and produced at uniform levels by all field strains of 
PRV, it must induce a detectable antibody response that persists over the time 
interval for which serologic monitoring is typically done, the deleted antigen 
must not be necessary for adequate protection against infection, and the 
antigenic variation of the diagnostic antigen must not be so great as to affect 
the ability of the diagnostic test to reliably and accurately detect pigs that have 
been infected with PRV.68 
Vaccination has been shown to reduce mortality, viral shedding, and the 
severity of clinical signs in pigs subsequently infected with virulent 
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PRV.2,25,27,66 However, vaccination will not prevent infection of pigs or the 
establishment of latent infections in pigs exposed to virulent strains of 
PRV.25,27,75,102 Therefore, vaccination alone will not lead to the eradication 
of PRV from infected swine herds. It is necessary that infected pigs, including 
latently infected pigs, be identified and removed from the swine population. 
This may best be accomplished by the widespread serological surveillance of 
the swine population, with subsequent culling of those pigs that have been 
exposed to field strains of PRV.118 
Serological Assays for Pseudorabies Virus 
A wide variety of serology tests have been devised over the years for the 
detection of the humoral immune response to pseudorabies virus. 
The standard serological diagnostic procedure for PRV in recent years has 
been the serum virus neutralization (SVN) test.7,14,41 The earliest reference 
in the literature to the SVN test for PRV was by Glover in 1938.32 The test is 
now commonly performed in microwell plastic assay plates, using porcine 
kidney (PK-15) or other susceptible tissue culture cell lines.41 Wittman125 and 
others report that the sensitivity .of the .SVN test depends on a number of 
factors: the type of cell culture, the use of a macro- or microtest, the 
concentration of cells used, the dose of virus used, whether sera is heat 
inactivated and, if so, for how long and at what temperature, the length of 
time and the temperature of the serum-virus incubation period, the presence 
or absence of complement, the length of time of the final incubation period 
following the addition of the cells, the type of dilutor used, and so on. Bitsch 
and Eskildsen 14, 15 found that increasing the incubation of the serum-virus 
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mixture at 37°C from 1 hour to 24 hours dramatically increased the sensitivity 
of the test. The addition of guinea pig or rabbit complement was found to be 
necessary to detect neutralizing antibody during the very early (four to eight 
or nine days postchallenge) immune response.14,15 Complement was found 
to be necessary to detect the initial IgM response, as well as that of 
complement requiring IgG subclasses, which were found to predominate in 
the early immune response.14,15 This finding was supported by the work of 
Rodak et al.,94 who were unable to demonstrate neutralizing IgM antibodies 
in an SVN assay lacking complement, even if IgM was present in high titers. 
Complement independent neutralization was found to be dependent on the 
appearance of IgG antibodies at about seven or eight days following infection. 
The standard SVN procedure used in the United States41 is not optimized for 
sensitivity, according to the previously mentioned findings. The 
recommended incubation period of the serum-virus mixture is .one hour at 
37°C, no complement is added, and the test is read after 48 hours.41 
A variety of assays have been devised for the detection of the humoral 
immune response to PRV. These include the complement fixation test 
(CFI),30 the microimmunodiffusion test (MIDT),36 the indirect 
radioimmunoassay (IRIA),49 the radial immunodiffusion enzyme assay 
(RIDEA),46 the countercurrent immunoelectrophoresis test (CIET),101 
radioimmunoprecipitation (RIP),121 the indirect hemagglutination (IHA) 
test,37 an Elisadisc test,6 a dot enzyme test,3 and numerous noncommercial 
enzyme-linked immunosorbent assays (ELISAs).17,78,107,109 However, none 
of these alternate test procedures supplanted the SVN test in veterinary 
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diagnostic laboratories in the United States on a widespread basis prior to the 
commercial availability of PRV serology diagnostic test kits in 1986. 
Requirements for special instrumentation, new technique development, or 
the lack of standardized test protocols has restricted the use of these 
procedures primarily to research applications. 
The ELISA has been found to offer superior sensitivity as compared to the 
SVN test, as well as the capability to perform larger numbers of serum assays 
in a shorter period of time, at relatively low expense.7,17,29,94 The 
development of a standardized PRV ELISA procedure106 at the National 
Veterinary Services Laboratories (NVSL) set the stage for the current 
proliferation of commercially available ELISA kits in the United States. 
However, the NVSL PRV ELISA required that a laboratory perform certain 
time consuming operations no longer necessary with the commercial kits, 
such as the coating of microtitration wells with antigen, and the titration of 
the enzyme conjugate.106 Consequently, this assay was somewhat tedious to 
perform, and its use at the Iowa State University Veterinary Diagnostic 
Laboratory was restricted mainly to the testing of either toxic sera or sera with 
low SVN titers. 
Table 3 lists the commercial PRV serology diagnostic kits currently 
licensed in the United States, as well as their license dates, manufacturer, and 
companion marker vaccines. This table contains information gathered from 
various sources.50, 122 
Commercially available diagnostic kits for the serological detection of 
antibodies to PRV in swine first appeared in the United States in January, 
Table 3. Commercially available pseudorabies serology diagnostic kits (November, 1991) 
Kit License Manufacturer/ Companion Diagnostic 
date distributor vaccines antigen 
Screening Assays: 
DiaSystems® CELISA PRV™ 8/89 TechAmerica TM Diagnostics none PRV (gJI) 
(IDEXX Laboratories) 
HerdChek®:Anti-PRV (5) 1/86 IDEXX Laboratories nore PRY 
H erdChek®:Anti-PRV (V) 1/86 IDEXX Laboratories none PRV 
Pseudorabies Virus Antibody 5/86 Viral Antigens nore PRY 
Test Kit - Latex Agglutination 
N 
0 
Differential Assays: 
C linEase-PRV® 10/89 SmithKline Beecham PR-Vac (MLV & killed) gl 
DiaSystems® CELISA 6/ 90 TechAmerica TM Diagnostics OmniMark™ PRV gIII 
OmniMark™ PRY 
H erdChe k®:Anti-PRV-gpX 8/88 IDEXX Laboratories SyntroVet PRY / Marker® gX 
SyntroVet PRY / Marker Gold® gX 
HcrdChe k®:Anti-PRV-gl 5/90 IDEXX Laboratories BioCeutic gl 
SyntroVet PRY / Marker Gold® gl 
PR-Vac (MLV & killed) g l 
TOLVID® Diagnostic 11/89 Agdia, Inc./The Upjohn Co. TOLVID® gX 
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1986,122 with the introduction of the IDEXX HerdChek® anti-PRV screening 
and verification ELISAs.33,108 A latex bead agglutination test (Pseudorabies 
Virus Antibody Test Kit - Latex Agglutination) from Viral Antigens Inc. was 
next licensed in May, 1986.100,101 These assays detected humoral immune 
responses both to infection with PRV and to vaccination with either killed or 
modified live virus (MLV) vaccines, and are classified as screening assays. 
The first commercial kit designed to distinguish between vaccinated and 
infected pigs, defined as a differential ELISA, was licensed in August, 1988. 
The IDEXX HerdChek anti-gX assay20 is a competitive ELISA (CELISA) 
designed to be used as a companion differential test for the SyntroVet 
PRV /Marker® MLV vaccine.19 A CELISA33 from TechAmerica™ 
(DiaSystems® CELISA PRV™) was next licensed in August, 1989. This assay 
is similar to the HerdChek anti-PRV ELISA and the latex agglutination test 
(LAT) in that it does not distinguish between infected and vaccinated pigs. In 
October, 1989, Norden Laboratories (now SmithKline Beecham) released a gI 
differential ELISA, ClinEase-PRV®, for use with their ML V and killed PRV 
vaccines, PR-Vac (killed and MLV).69 This release was followed closely by the 
licensing, in November, 1989, of Agdia's differential gX CELISA (Tolvid® 
Diagnostic) for use with the Tolvid® MLV vaccine60 produced by The 
Upjohn Company. Two more differential ELISAs have been licensed more 
recently: TechAmerica™ Diagnostics' DiaSystems® CELISA OmniMark™ 
PRV kit52 for use with the OmniMark™ PRV gIII deleted vaccine from 
NovaGene, Inc.,54 and IDEXX Laboratory's HerdChek®:Anti-PRV-gI CELISA 
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kit for use with any of three gl deleted marker vaccines (from SmithKline 
Beecham, SyntroVet, and Boehringer / lngelheim). 
The PRV serology diagnostic kits listed above are all available 
commercially, and are licensed by the United States Department of 
Agriculture (USDA) for use by state-accredited diagnostic laboratories. 
Particle Concentration Fluorescence Immunoassay (PCFIA) 
The particle concentration fluorescence immunoassay (PCFIA) evaluated 
here is the first test of this type for the detection of antibodies to PRV. 
Previous research applications of the PCFIA technique include the detection 
and quantitation of human immunoglobulins, 1,45,57,58,62,79 murine 
immunoglobulins45 and murine antiviral antibodies,82,83 and the detection 
of various endogenous proteins.26,42 The PCFIA technique has also been 
used to detect the presence of drugs in race horses,56,63,104,114,126 and 
commercial tests are available for this purpose. A commercial PCFIA for the 
detection of antibodies to Brucella abortus in cattle74,107 was licensed122 in 
1987 by the manufacturer that developed the PRV PCFIA.i 
IDEXX Labora tories, Inc., One fDEXX Drive, Westbrook, Maine. 
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MATERIALS AND METHODS 
Swine Sera 
Positive illlll negative fi.tld swine SfU 
For this portion of the study, 2,262 field serum samples from 
nonvaccinated swine herds of known status for PRV infection were 
evaluated by the PCFIA. 
Positive ficld swine SfU Sera included in the positive population set of 
field swine sera (n=619) had previously tested positive by at least two 
conventional PRV serological assays, including the serum virus 
neutralization (SVN) test. The SVN test results were considered to be 
positive at an endpoint dilution of~ 1:2. The HerdChek screening ELISA was 
used to verify the SVN positive result for nearly all samples, but a small 
number of the sera were verified as positive by the latex agglutination test 
(LAT) instead. The PRV positive field sera were obtained from 
nonvaccinated pseudorabies infected herds s~bmitted to the Iowa State 
University Veterinary Diagnostic Laboratory as part of the Iowa Pseudorabies 
Disease Program. 
Negative ficld swine SfU All sera in the negative population set of field 
swine sera (n=1643) had been previously tested as negative by the IDEXX 
HerdChek® screening ELISAk for PRV antibodies. The negative set consisted 
of sera that were obtained from nonvaccinated pseudorabies-free swine herds 
for which sera had been submitted to the Veterinary Diagnostic Laboratory. 
k IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine. 
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Challenged pig antisera 
An additional 241 sera were collected from 35 experimentally infected 
nonvaccinated pigs ranging from 4 to 11 weeks of age at the initiation of the 
study. Sera were collected daily from day 4 postchallenge (PC) to day 10 PC, 
then again at days 14 and 21 PC. The challenge virus strain of PRV was either 
the Becker strain or the pneumotropic strain VDL 4892.20 Challenge doses 
were administered intranasally, and ranged from 10s to 107 TCIDso of virus 
per pig (Table 4 summarizes this information). These sera were then tested by 
the experimental PCFIA for PRV, as well as by eight other PRV serological 
assays currently in use at the Veterinary Diagnostic Laboratory. 
NVSL PRV check ill 
The 1990 PRV ELISA screen and latex agglutination test check set of 30 
swine sera was provided by the National Veterinary Services Laboratories 
(NVSL).l 
Weak positive md. suspect~ 
A set of 619 swine sera determined to be either weakly positive or suspect 
by the HerdChek PRV screening ELISA was selected from field samples 
submitted to the Veterinary Diagnostic Laboratory. Criteria used for selection 
were that the sera had tested either weakly positive (S/ P ratio of 0.43 to 1.00) 
or as suspect (S / P ratio of 0.38 to 0.43) on the screening ELISA. 
1 National Veterinary Services Laboratories, Ames, Iowa. 
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Table 4. Groups of pigs infected intranasally with pseudorabies virus 
Sample # Group ID Pig ID Age Strain of PRV Dose 
(weeks) (TCID50) 
1 802-15 66 8 Becker 4.9x106 
2 67 
3 68 
4 69 
5 70 
6 804-8 396 4 ISU 4892 3.7 x 107 
7 397 
8 398 
9 399 
10 400 
11 804-9 81 10-11 ISU 4892 3.7x107 
12 82 
13 83 
14 84 
15 85 
16 86 
17 87 
18 88 
19 89 
20 90 
21 91-2 113 4-5 ISU 4892 2.1x106 
22 114 
23 115 
24 116 
25 117 
26 802-19 71 10-11 Becker 4.1x106 
27 72 
28 73 
29 74 
30 75 
31 802-19 118 10-11 ISU 4892 5.0x10s 
32 119 
33 120 
34 121 
35 122 
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Plugged wells 
Swine sera of poor quality can cause the filter at the bottom of the assay 
plate microwell to become clogged, an occurrence described as a "plugged 
well". Sera causing plugged wells on initial testing by the PCFIA were 
characterized according to the criteria of clarity, color, the presence of 
particulates, and the freshness of the sample. Attempts were also made to 
treat the offending sera, first by centrifugation (3000 rpm for 15 min) and 
finally by filtration (0.2 µm).m 
Serological Assays 
PCFIA 
PCFIA reagents Reagents for the PRV PCFIA were supplied by 
IDEXX Laboratories as part of an experimental test kit." The solid phase 
consisted of 0.6-0.8 µm polystyrene latex particles coated with PRV antigen 
(Shope strain), diluted in phosphate buffered saline (PBS) with protein 
stabilizers, and preserved with sodium azide and thimerosal. The conjugate 
consisted of a monoclonal antibody to the gII glycoprotein of PRV, labelled 
with phycoerythrin, a high-output fluorophore. Strong positive, weak 
positive and negative control antisera to PRV were provided pre-diluted in 
sample diluent. Sample diluent consisted of PBS with protein stabilizers and 
preservatives. The wash solution consisted of PBS and preservatives. 
m Spin-XTM centrifuge filter unit, 0.22 µm cellulose acetate, Costar®, 205 Broadway, 
Cambridge, MA. 
n IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine. 
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PCFIA Assay Plates Specially designed 96 well assay plates similar in 
appearance to standard microtiter plates were used. A 0.2 µm cellulose acetate 
filter located at the base of each microwell allowed the rinsing and removal of 
all well contents not bound to the latex particles by the use of a vacuum 
applied to the plate by the Screen Machine. The vacuum was applied to a port 
that communicated with a sump area beneath the membrane filter in each 
plate (Figure 1). 
PCFIA Assay Procedures The PCFIA for antibodies to PRV is a 
competitive or blocking fluorescence immunoassay. PRV-coated polystyrene 
particles serve as the solid phase. Diluted test sera are incubated with the 
coated particles, and antibodies directed against PRV antigens became attached 
to the solid phase. A conjugate is then added to the test well and allowed to 
compete with sample antibodies for sites on the antigen . The conjugate used 
for this evaluation consisted of a monoclonal antibody (MAb) directed against 
the gII PRV antigen, which is present in all strains of PRV. The MAb was 
labeled with the fluorophore phycoerythrin. Fewer antigenic sites are 
available for the conjugate if a serum sample contains anti-PRV gII 
antibodies. Conversely, a serum sample with no anti-PRV antibodies will not 
block the antigenic sites, allowing the labeled conjugate to attach to the coated 
particles. Any unattached conjugate is removed during the filtration and 
wash steps, resulting in lower photon counts for those wells containing sera 
from swine exposed to PRV. 
The Screen Machine consists of a multi-purpose automated instrument 
designed to perform the various reagent dispense, incubation, and wash steps, 
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WELL CROSS-SECTION 
SUMP 
Figure 1. Cross-section of a PCFIA assay plate well, showing the 
membrane filter, the vacuum port, and the sump 
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in addition to detecting the fluorescence at specific wavelengths in each well. 
Certain maintenance and calibration procedures were performed at regular 
intervals. For this study, the following calibration procedures were 
performed as part of each assay: a lamp calibration routine, an assay using 
reference performance verification particles (PVPs), and a reference plate 
assay. ·The PVP assay provided information concerning all aspects of 
instrument performance, including pipetting accuracy, separation (vacuum), 
and fluorimetry performance. The reference plate assay provided 
information specifically about the fluorimetry performance . 
. A partitioned tray was filled with the following test reagents: PRV-coated 
polystyrene particles, anti-PRV gll:phycoerythrin conjugate, and wash 
solution. The reagent tray was inserted into the Screen Machine for 
automated dispensing. 
The PCFIA procedure required the addition of 12 negative control 
samples and two each of strong and weak positive control samples to the first 
assay plate of each batch run. A batch run consisted of from 1 to 10 plates. 
Fifty µl of prediluted control sera was added to the prescribed well, and 50 µl 
of sample diluent was added to each of the remaining wells. A 1:11 dilution 
of each serum was prepared by adding five µl of each serum sample to the 
wells containing sample diluent. 
The assay plates were then placed in a 10-plate capacity elevator tray in the 
Screen Machine for automatic dispensing of reagents, incubations, 
separations, and fluorescence detection. Coated particles (20 µl per well) were 
pipetted into each well, followed by a 14 minute incubation. Conjugate (20 µl 
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per well) was then pipetted into each well, followed by a 9 minute incubation. 
Vacuum was applied for 60 seconds, followed by a wash (50 µl per well). The 
Screen Machine is capable of reading fluorescence by three channels (channels 
A, B and C) simultaneously. The emission fluorescence of the bound 
phycoerythrin was read at 575 nm by channel C of the Screen Machine while a 
vacuum was applied to the plate (channel A had been reserved for the 
fluorophore, fluorescein isothiocyanate, which is used in a PCFIA for 
brucellosis). In addition, a reference particle using Texas red as a fluorophore 
was read at 620 nm by channel B. The reference particles had been previously 
mixed with the PRY-coated particles, and served to validate certain assay 
performance criteria, including proper filtering and pipetting. The test results 
were calculated as an S/ N value, which is the ratio of the test sample signal to 
the mean of the negative control sera signals. Test results were calculated as a 
ratio in order to minimize the effect of test to test variation. The signal 
values used to calculate the S/N value were themselves a ratio of the test and 
reference channel photon counts for each well. Thus, the SI N formula was 
defined as: 
S N _ Sample channel C counts/sample channel B counts 
I - Neg. control channel C counts/Neg. control channel B counts 
Other serological assays 
As mentioned previously, 241 swine sera from 35 intranasally infected 
pigs were tested by the PCFIA in an attempt to assess the ability of the PCFIA 
to detect the early immune response in infected pigs. These same sera were 
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also tested by eight other PRV serological assays in order to compare the 
performance of all of the PRV serological assays currently in use at the Iowa 
State University Veterinary Diagnostic Laboratory. Test results from the 
PCFIA were compared with results from each of the other eight assays by the 
chi-square method, testing the null hypothesis that the PCFIA and the 
compared test did not differ in the number of sera detected as positive (or 
suspect) and negative. 
The eight assays consisted of the serum virus neutralization (SVN) test, 
two commercial screening ELISAs (DiaSystems® CELISA PRVrM and 
HerdChek®:Anti-PRV (S)), four commercial differential ELISAs (ClinEase-
PRV®, DiaSystems® CELISA OmniMark™ PRV, HerdChek®:Anti-PRV-gpX, 
and HerdChek®:Anti-PRVgI), and a commercial latex agglutination test 
(Pseudorabies Virus Antibody Test Kit-Latex Agglutination). Tables 5 and 6 
summarize various features and characteristics of the experimental PCFIA 
and the seven commercial PRV antibody tests. The SVN test was performed 
essentially as described in the standard procedure adopted by the American 
Association of Veterinary Laboratory Diagnosticians (AA VLD) in 1977.41 All 
seven of the commercial .PRV antibody tests listed above were performed 
according to the manufacturers' instructions. 
Table 5. Comparison of the PCFIA for pseudorabies virus with six commercial ELISAs and the latex 
agglutination test 
Test name Test Type of Serum Antigen Conjugate Indicator Wavelength 
abbreviation test dilution (nm) 
PCFIA PCFIA PC FIA 1:11 PRV (gll) anti-PRV gll: NIAa 575 
(IDEXX) phycoerythrin 
HerdChek PRV Ab Screen IDEXX Screen indirect 1:20 PRV anti-swine IgG: ABTSC 405-410 
(IDEXX) ELISA HR Pb 
DiaSystems PRV Ab CELISA TA Screen CELIS A rone PRV anti-PRV gll: ABTS 405-410 
(TechAmerica) HRP 
HerdChek PRV gl Ab Test IDEXX gl CELIS A 1:2 PRV (gl) anti-PRV gl: TMBd 650 
(IDEXX) HRP 
(JJ 
ClinEase PRV gl Ab Test SKB gl indirect 1:5 PRV gl anti-swine IgG: ABTS 405-410 N 
(SmithKline Beecha m) ELISA HRP 
HerdChek PRV gpX Ab Test IDEXX gX CELIS A 1:2 PRV (gX) anti-PRV gX: TMB 650 
(IDEXX) HRP 
DiaSystems GIII PRV CELISA TA gIII CE LISA rone PRV g III anti-PRV glll: TMB 630 
(TechAme rica) HRP 
Latex Agglutination PRV Test LAT la tex 1:4 PRV NIA NIA NIA 
(Viral Antigens) agglutination 
a NI A = not applicable. 
b HRP = horseradish peroxidase. 
c ABTS = 2,2-azino-di(3-ethylbenzthiazoline sulfona te). 
d TMB = tetramethylbenzidine. 
Table 6. Result calculations and threshold values for the PCFIA and six commercial pseudorabies ELISAs 
Test name Result Result calculation Positive Negative Suspect 
threshold threshold range 
PRY PCFIA (IDEXX) 5/N Sam12le countLsam12Ie ref count :5 0.9oa > 0.90 rone 
Negative count/ negative ref count 
HerdChek® PRY Ab Screen 5;pb Sam12le OD - Ne&ative OOC > 0.43 < 0.38 0.38-0.43 
(IDEXX) Positive Ood - Negative OD 
DiaSystems PRY Ab CELISA raw OD none :5 the greater of: >threshold rone 
(Tech America) 0.32 x Negative OD, or 
Positive OD + 0.15 
HerdChek® PRY gl Ab Test 5/ Ne Sam12Ie OD <0.60 >0.70 0.60-0.70 
(IDEXX) Negative OD 
ClinEase PRY gl Ab Test s;cf 2 x Sam12l~ OD - N~~ativ~ QD >1.0 <0.80 0.80-1.00 
(SmithKline Beecham) Positive OD - Negative OD 
HerdChek® PRY gpX Ab Test SIN Sam12le QD <0.60 >0.70 0.60-0.70 
(IDEXX) Negative OD 
DiaSystems Giii PRY Ab CELl5A SI N Sam12le QD <0.65 >0.75 0.65-0.75 
(Tech America) Negative OD 
a 5/ N :5 0.90 selected as the positive threshold for this evaluation on the basis of results from other studies reported here. 
b S/ P = sample to positive control ratio. 
c Negative OD = mean negative control optical density. 
d Positive OD = mean positive control optical density. 
e 5/N =sample to negative control ratio. 
f 5/C = sample to positive control ratio. 
C>l 
C>l 
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RESULTS 
PCFIA Serology Results 
Positive m1d swine ~ 
The S/ N values for the 619 swine sera making up the positive population 
set of field swine sera ranged from 0.09 to 0.98 (Figures 2 and 4), with a mean 
S/ N of 0.36 and a standard deviation of 0.16. Only two positive set samples 
resulted in S/ N values greater than or equal to 0.90. Using a positive S/ N 
threshold of ~ 0.90, the sensitivity of the PCFIA was 99.7% for this group of 
known positive field sera. 
Negative .fi.dd swine~ 
The S/ N values for the 1,643 negative population set of field swine sera 
ranged from 0.71 to 2.04 (Figures 3 and 4), but were clustered tightly around 
the mean (mean S/ N = 1.09, standard deviation= 0.07). Only two samples 
resulted in S/ N values less than 0.90. Using a positive S/ N threshold of 
~ 0.90, the specificity of the PCFIA was 99.9% for this set of known negative 
field sera. 
Challenged pig antisera 
A total of 241 sera from 35 pigs experimentally infected with PRV were 
tested by the PCFIA. If a positive S/ N threshold of~ 0.90 is used, the PCFIA 
detected 0% of the sera as positive at 5 days postchallenge (PC), 50% at 6 days 
PC, 82% at 7 days PC, and 100% at days 8 through 23 PC (Figures 5-11 and 
Tables 7 and 8). 
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Figure 2. PCFIA S/N frequency distribution for pseudorabies positive swine population (n = 619 sera). 
Sera were collected from nonvaccinated commercial swine herds. A positive threshold of 
S/N s-; 0.90 resulted in a sensitivity of 99.7% for the PCFIA 
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Figure 3. PCFIA S I N frequency distribution for pseudorabies negative swine population (n = 1,643 sera). 
Sera were collected from nonvaccinated commercial swine herds. A positive threshold of 
S I N s; 0.90 resulted in a specificity of 99.9% for the PCFIA 
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Figure 4. PCFIA S/ N frequency distribution for pseudorabies negative (n = 1,643 sera) and pseudorabies 
positive (n = 619 sera) swine populations. Sera were collected from nonvaccinated commercial 
swine herds. A positive threshold of S/ N ~ 0.90 was selected for evaluation of the PCFIA 
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Figure 5. 5 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at five days postchallenge (n = 35) 
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Figure 6. 6 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at six days postchallenge (n = 32) 
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Figure 7. 7 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at seven days postchallenge (n = 28) 
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Figure 8. 8 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at eight days postchallenge (n = 25) 
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Figure 9. 9 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at nine days postchallenge (n = 24) 
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Figure 10. 10 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at 10 days postchallenge (n = 22) 
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Figure 11. 14 days PC: percent swine serum samples detected as positive or suspect by nine serological 
assays at 14 days postchallenge (n = 21) 
Table 7. Comparison of results from nine PRV serological tests in the detection of the early immune 
resr onse in rigs 5 to 7 da~s after exrerimental infection with rseudorabies virus 
Test Dais PC No. sera No. eositive/suseect No. ne~ative 3 eositive pa 
PC FIA 5 35 0 35 0.0 
IDEXX screen 5 35 0 35 0.0 n.s.b 
TA screen 5 35 0 35 0.0 n.s. 
SYN 5 33 0 35 0.0 n.s. 
LAT 5 35 7 28 20.0 < 0.01 
IDEXX gl 5 35 0 35 0.0 n.s. 
SKB gl 5 35 0 35 0.0 n.s. 
IDEXX gX 5 35 0 35 0.0 n.s. 
TA gIII 5 35 0 35 0.0 n.s. 
PC FIA 6 32 16 16 50.0 
IDEXX screen 6 32 2 30 6.3 < 0.001 
TA screen 6 31 13 18 41.9 n.s. 
SYN 6 32 0 32 0.0 < 0.001 ,p. U1 
LAT 6 32 26 6 81.3 < 0.01 
IDEXX gl 6 32 0 32 0.0 < 0.001 
SKB gl 6 32 0 32 0.0 < 0.001 
IDEXX gX 6 32 1 31 3.1 < 0.001 
TA gIII 6 32 0 32 0.0 < 0.001 
PC FIA 7 28 23 5 82.0 
IDEXX screen 7 28 25 3 89.3 n.s. 
TA screen 7 23 22 1 95.7 n.s. 
SYN 7 28 0 28 0.0 < 0.001 
LAT 7 28 28 0 100.0 < 0.05 
IDEXX gl 7 28 5 23 17.9 < 0.001 
SKB gl 7 28 3 25 10.7 < 0.001 
IDEXX gX 7 28 3 25 10.7 < 0.001 
TA gIII 7 28 9 19 32.1 < 0.001 
a P = the probability that the results from the PCFIA and the compared test do not differ, as calculated by the chi-square test. 
b n.s. = no statistical difference between the PCFIA and the compared test. 
Table 8. Comparison of results from nine PRV serological tests in the detection of the early immune 
resEonse in Ei~s 8 to 10 dals after exEerimental infection with Eseudorabies virus 
Test Da_rs PC No. sera No. eositive/suseect No. negative 3 eositive pa 
PCFIA 8 25 25 0 100.0 
IDEXX screen 8 25 25 0 100.0 n.s.b 
TA screen 8 25 25 0 100.0 n.s. 
SVN 8 25 3 22 12.0 < 0.001 
LAT 8 25 25 0 100.0 n.s. 
IDEXX g l 8 25 18 7 72.0 < 0.005 
SKB gl 8 25 17 8 68.0 < O.Ql 
IDEXX gX 8 25 19 6 76.0 < O.Ql 
TA g lll 8 25 23 2 92.0 n .s. 
PCFIA 9 24 24 0 100.0 
IDEXX screen 9 24 24 0 100.0 n .s. 
TA screen 9 24 24 0 100.0 n.s. 
SVN 9 24 9 15 37.S < 0.001 .p.. 
°' LAT 9 24 24 0 100.0 n.s. 
IDEXX gl 9 24 23 1 95.8 n .s. 
SKB gl 9 24 22 2 91.7 n.s. 
IDEXXgX 9 24 22 2 91.7 n.s. 
TA glll 9 24 24 0 100.0 n .s. 
PCFIA 10 22 22 0 100.0 
IDEXX screen 10 22 22 0 100.0 n.s. 
TA screen 10 22 22 0 100.0 n .s. 
SVN 10 22 15 7 68.2 < 0.005 
LAT 10 22 22 0 100.0 n.s. 
IDEXX gI 10 22 21 1 95.5 n.s. 
SKB g l 10 22 21 1 95.5 n.s. 
IDEXX gX 10 22 22 0 100.0 n.s. 
TA g III 10 22 22 0 100.0 n.s. 
a P = the probability that the results from the PCFIA and the compared test do not differ, as calculated by the chi-square test. 
b n.s. = no statistical difference between the PCFIA and the compared test . 
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Results for the eight other PRV antibody tests are presented alongside the 
PCFIA data in Figlires 5-11 and in Tables 7 and 8. The latex agglutination test 
appeared to be more sensitive than the PCFIA in detecting the early immune 
response to infection with PRV. Results of the PCFIA were significantly 
different from those of the LAT on days 5 and 6 postchallenge (P < 0.01), and 
on day 7 postchallenge (P < 0.05). The PCFIA appeared to be more sensitive 
than the SVN test for this set of swine sera. Results of the PCFIA were 
significantly different than those of the SVN test on days 6 through 9 
postchallenge (P < 0.001), and on day 10 postchallenge (P < 0.005). The PCFIA 
results did not differ significantly on any test date with the TechAmerica 
screening ELISA. The PCFIA results differed significantly from those of the 
IDEXX screening ELISA only for day 6 postchallenge (P < 0.001). 
The PCFIA appeared to be more sensitive than all four differential ELISAs 
for days 6 and 7 postchallenge (P < 0.001). On day 8 postchallenge, the PCFIA 
results differed significantly from those of the IDEXX gl (P < 0.005), the 
SmithKline Beecham gl (P < 0.01), and the IDEXX gX tests (P < 0.01), but not 
from those of the TechAmerica glll ELISA. By days 9 and 10 postchallenge, no 
significant differences were found between test results from the PCFIA and 
the differential ELISAs. 
Figure 12 and Table 9 summarize the respective performance of each test 
regarding four key parameters: the time (number of days postchallenge) 
required to detect at least one, 95%, and 100% of the sera as either positive or 
suspect, and the time from initial detection to ~ 95% detection. Suspect 
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Figure 12. Comparison of the time (number of days postchallenge) required for nine serological assays to 
detect at least one, 953, and 1003 of the postchallenge swine serum samples as either positive 
or suspect for antibodies against pseudorabies virus (n=35 at day 4 postchallenge, n=35 at day 5, 
n=32 at day 6, n=28 at day 7, n=25 at day 8, n=24 at day 9, n=22 at day 10, and n=21 at day 14) 
Table 9. Comparison of results from nine PRV serological tests in the detection of the early immune 
resEonse in pigs to intranasal infection with £Seudorabies virus 
Test name Initial PRV ~ 953 PRV 1003 PRV Time from initial 
detection detection detection to ~ 953 detection 
PRV PCFIA (IDE.XX) 6daysPC 8daysPC 8daysPC 2days 
HerdChek PRV Ab Screen 6daysPC 8daysPC 8days PC 2days 
(IDE.XX) 
DiaSystems PRV Ab CELISA 6daysPC 7daysPC 7daysPC 1 day 
(TechAmerica) 
Serum virus neutralization 8daysPC 14daysPC 14daysPC 6days 
Latex agglutination PRV Test SdaysPC 7daysPC 7daysPC 2days 
,p. 
\() 
(Viral Antigens) 
HerdChek PRV gI Ab Test 7daysPC 9daysPC 14daysPC 2days 
(IDE.XX) 
ClinEase PRV gI Ab Test 7daysPC 10 days PC 14 days PC 3days 
(SmithKline Beecham) 
HerdChek PRV gpX Ab Test 6 days PC 10 days PC 10 days PC 4days 
(IDE.XX) 
DiaSystems Giil PRV CELISA 7daysPC 9days PC 9daysPC 2days 
(TechAmerica) 
50 
results were pooled with positive results using the rationale that either result 
is cause for further action in our laboratory, whether it be retesting the serum, 
rebleeding. the pig, or simply reporting the result as it stands. 
NVSL PRV checkm 
Evaluation of the PCFIA using the 1990 PRV check test for ELISA screen 
and latex agglutination tests, provided by the National Veterinary Services 
Laboratories, resulted in a range of S/ N values from 0.22 to 1.26, with no 
overlapping of sample values classified as positive or negative by the NVSL. 
All positive check test sera S I N values were less than or equal to 0.90. All 
negative check test sera S/ N values were greater than 1.02. Using a positive 
S/ N threshold of~ 0.90, all check set samples were correctly identified by the 
PCFIA. 
Weak positive .and suspect &n 
A total of 619 field sera from unvaccinated swine were tested by the 
PCFIA after previously being identified as weakly positive or suspect by the 
HerdChek Screening ELISA for PRV.0 Samples determined to be weakly 
positive included 376 sera with S/ P values from 0.43 to 1.00. The suspect 
("retest") group of samples included 279 sera with S/ P values from 0.38 to 
0.43. All 619 swine sera were also tested by the latex agglutination test (LAT) 
for PRV.P The results indicate a close match between the LAT and PCFIA 
when 0.90 is used as the positive threshold for the PCFIA (Table 10). The LAT 
0 IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine. 
P Viral Antigens Inc., Memphis, Tennessee. 
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and PCFIA agreed on 92% of the sample results while the PCFIA results 
matched those from the ELISA for only 2% of the samples. A total of 571 sera 
determined to be weakly positive or suspect by the ELISA were negative by 
both the LAT and the PCFIA. 
Table 10. Summary of PRV PCFIA and latex agglutination test (LAT) serology 
results for 619 swine sera determined to be either weakly positive 
(S/P from 0.43 to 1.00) or suspect (S/P from 0.37 to 0.43) on the 
IDEXX HerdChek screening ELISA 
LAT negative 
LAT positive 
Total 
Plugged wells 
PCFIA negative PCFIA positive Total 
571 
10 
581 
12 
26 
38 
583 
36 
619 
The incidence of plugged wells on the PCFIA ranged from 1-2% for the 
routine testing of fresh samples, to more than 10% for sera of poor quality. A 
total of 216 sera causing plugged wells were identified and described, and 145 
of these were treated by centrifugation. This treatment resulted in 81 (66%) of 
the sera no longer causing plugged wells, while 64 sera (44%) continued to 
cause plugged wells. Filtration of 28 of the 64 sera that continued to cause 
plugged wells resulted in only 2 plugged wells (7%). 
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Of the 216 sera causing plugged wells initially, only six (2.8%) were 
described as "normal" in appearance according to the criteria of color, clarity, 
presence of particulates, and viscosity (Table 11). The majority of samples 
causing plugged wells were identified as abnormal in appearance: 79.2% by 
abnormal color, 81 .9% by abnormal clarity, 88.9% by the presence of 
particulates, and 39.8% by abnormal viscosity. 
Table 11. Visual description of 216 swine sera causing plugged wells on the 
PCFIA for PRV 
Color Clarity Particulates Viscosity 
No. % No. % No. % No. % 
Normal 45a 20.8% 39 18% 24 11.1 % 130 60.2% 
Abnormal 171b 79.2% 177c 81.9% 192d 88.9% 86e 39.8% 
a Slightly hemolyzed (red or brown) sera were classed with normal 
colored sera. 
b Abnormal color descriptions ranged from red to dark brown or green. 
c Abnormal clarity descriptions ranged from cloudy to opaque. 
d Precipitates (white or otherwise) were the most frequently described 
particulates. 
e Abnormal viscosity descriptions ranged from slightly thick to clotted 
blood. 
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SUMMARY AND DISCUSSION 
This study evaluated a screening PCFIA for antibodies to pseudorabies 
virus by the testing of a wide variety of sera, including those from swine 
herds of known PRV exposure and vaccination status, and experimentally 
infected pigs. The true status of each field serum was inferred by the results 
from conventional serology tests used in the Iowa State University 
Veterinary Diagnostic Laboratory, including the serum virus neutralization 
test, a screening ELISA, and a latex agglutination test. Results of this testing 
indicated that the PCFIA for PRV reliably detected the presence of antibodies 
to PRV in swine sera at a sensitivity and specificity comparable or superior to 
other commonly used serological assays, including the ELISA, the serum 
virus neutralization test and the latex agglutination test. 
This study was intended to provide information that would facilitate the 
setting of threshold S/ N values for the interpretation of test results. The 
optimal threshold for a screening assay would theoretically maximize test 
sensitivity while maintaining an acceptable level of test specificity. Thus, the 
threshold should identify nearly all true positive pigs (minimize false 
negatives), but should minimize the number of true negative pigs incorrectly 
identified as exposed to PRV (minimize false positives). The tight grouping 
of the negative population around the mean observed here allowed the 
establishment of a positive threshold at a level high enough to ensure 
adequate sensitivity of the test for screening purposes. 
A positive threshold set at S/ N ::;; 0.90 resulted in extremely high levels 
(>99%) of both sensitivity and specificity for the positive and negative pools of 
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field sera. However, these groups of field sera were deliberately chosen as 
well defined groups that might be expected to lead to such results. The 
positive group of field sera had all tested positive previously by the SVN test 
with a serum dilution of 1:2 or greater. We consider the SVN test procedure 
performed in our laboratory to be a screening assay of low to moderate 
sensitivity, but high specificity. Therefore, sera testing positive on the SVN 
test would be expected to be detected as positive by an assay that was designed 
to perform comparably to the more sensitive ELISA screening assay. 
Similarly, the negative group of field sera had all previously tested negative 
by the extremely sensitive screening ELISA, and therefore probably did not 
contain many borderline sera that might cause problems on the PCFIA. 
Nonetheless, the PCFIA performed well with these groups of field sera, and 
did not produce any unexpected results. 
The sensitivity of the test in detecting the early immune response in 
experimentally infected pigs was quite good in comparison with the eight 
other assays these samples were tested by. Figure 12 and Tables 7, 8 and 9 
provide a summary of the ability of the nine PRV antibody tes ts to detect the 
early antibody response to experimental infection of young pigs. The 
statistical significance of the results from the PCFIA as compared with each of 
the other eight assays is indicated in Tables 7 and 8, as determined by the chi-
spuare test. 
The PCFIA initially detected at least one serum sample as positive at 6 
days postchallenge (PC). The time to initial detection of at least one serum 
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sample as positive or suspect for the other eight tests ranged from 5 days PC 
for the latex agglutination test to 8 days PC for the SVN test. 
The PCFIA detected 100% of the challenged swine sera as positive by day 8 
PC. The other eight tests required from 7 days PC (for the Tech America 
screening ELISA and the latex agglutination test) to 11-14 days PC (for the 
SVN test, the HerdChek gI ELISA, and the ClinEase gI ELISA) to detect 100% 
of the sera as positive or suspect. 
Generally, the screening assays, including the PCFIA, initially detected 
positive sera earlier than the differential assays, and also detected the majority 
of sera as positive more quickly as well. The exception to this generalization 
was the SVN test, which performed poorly with this group of swine sera. The 
SVN test did not detect any positive sera until 8 days PC, and did not detect 
100% of the sera as positive until 14 days PC. This latter value may be 
misleading, because sera were not collected between day 10 and day 14 PC, so 
that the majority of sera may actually have been detected by the SVN 
somewhat earlier than is indicated here. Also, as was discussed in the 
literature review, the procedure followed in our laboratory for the SVN test 
would not be expected to perform well in this comparison, because it cannot 
detect the early IgM response in the absence of supplemental complement. 
For similar reasons, the superior performance of the LAT at detecting the 
early immune response is not surprising, because IgM is known to be highly 
efficient in agglutination reactions (reportedly about 750 times as efficient as 
IgG).110 These results also confirmed an earlier report concerning the high 
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sensitivity of the LAT in comparison with the SVN and ELISA screen tests, 
especially for the early immune response.101 
The specificity of the PCFIA was measured, in part, by the large negative 
field sera group, but also by the testing of the group of 619 field sera that had 
tested as weakly positive or suspect by the screening ELISA. The majority of 
this group of sera (583 of the 619 sera tested) were confirmed by neither the 
LAT nor the SVN test in our laboratory, and we consider them to be false 
positive results. The close correlation (92%) between the PCFIA and the LAT 
results for this type of sample may be a significant feature of the PCFIA for 
laboratories experiencing a high rate of unconfirmed retests of screening 
ELISA results. 
Plugged microwells are a hazard unique to the PCFIA technique. The 
process by which the unbound reagents and sera are removed from the 
reactant wells involves filtration under a vacuum through a filter at the 
bottom of the wells. Sera containing particulate or other insoluble material, 
such as lipid films or bacteria, can plug the filter and prevent the removal of 
unbound reagents, and also prevent concentration of the coated particles at 
the surface of the filter. These occurrences are termed plugged wells, and 
constitute an invalid test. The incidence of plugged wells has not proven to 
be of great importance in the testing of bovine sera by the brucellosis PCFIA,q 
but swine sera is frequently of lower quality, and often contains a lipid layer 
on the surface. An evaluation of the incidence of plugged wells using the 
PRV PCFIA was consid ered an important aspect in the determination of the 
q Personal communication from Peggy Jo Fague, IDEXX Laboratories, One IDEXX Drive, 
Westbrook, Maine. 
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practicality of the assay for routine screening in a veterinary diagnostic 
laboratory. Our experience with the occurrence of plugged wells strongly 
indicates that the PCFIA requires good quality sera to be practical in a real 
world setting. However, this may prove to be more of an aid than a 
hindrance to a desired result of valid test results. Poor quality sera may 
produce inaccurate results in assay procedures that do not call attention to 
conditions such as heavy bacterial contamination, or the presence of 
particulate material. The PCFIA requires that the test serum be reasonably 
free of such contaminants, and provides a validation procedure to ensure that 
such is the case. A plugged well rate of 1-23 was routine in this study for sera 
that was less than one week old and in what we consider to be "normal" 
condition (not cloudy, greatly discolored, containing particulate matter, or 
highly viscous in nature). This is a rate of retesting that would appear to be 
reasonable, considering the speed with which an assay can be completed . 
Samples causing plugged wells could be retested by another procedure, or a 
replacement sample of higher quality could be requested for retesting by 
PCFIA. Preselection of abnormal appearing sera, and removal for testing by 
another procedure, might be a practical method of lowering the rate of 
plugged well occurrence, since about 80-903 of the sera causing plugged wells 
were abnormal in appearance. Data presented here indicate this rate could be 
decreased even further if routine centrifugation was made part of the sample 
preparation routine. Centrifugation and the use of kaolin to adsorb 
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contaminants have been used successfully to decrease plugged well rates by 
laboratories using the PCFIA for brucellosis.r 
The specific S/ N values obtained from performing the PCFIA may be 
expected to vary depending on alteratiqns made to reagents, controls and 
assay procedures. Simply substituting a negative control with a higher 
photon count will shift all S/ N values down a corresponding degree. The 
results reported here reflect the particular configuration of test procedures, 
reagents and negative control sera provided by the manufacturer in the 
experimental kits under evaluation. 
The PCFIA enabled the rapid testing of larger numbers of sera than would 
be practical using alternative methods. Estimates of the number of sera that 
could be tested by the PCFIA are presented in Table 12.107 A single technician 
is estimated to be able to test up to 2,880 sera per day, or up to 748,800 sera per 
year. Commercial availability of a PCFIA for PRV would greatly facilitate the 
rapid testing of the large numbers of swine sera that has been mandated by 
the national pseudorabies eradication program. 
r Personal communication from Peggy Jo Fague, IDEXX Laboratories, One IDEXX Drive, 
Westbrook, Maine. 
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Table 12. Estim ate of the instrument throughput and technician time for 
the PCFIA for antibody to pseudorabies virus107 
Batch runs Samples Tech. time Samples 
Instruments Technicians per daya per day per sampleb per year 
1 1 3 2,880 10 sec 748,800 
1 1-1.5 4 3,840 11 sec 998,400 
1 2 5 4,800 12 sec 1,248,000 
2 2 7 6,720 9 sec 1,747,200 
2 3 10 9,600 9 sec 2,496,000 
a Instrument completes 10 plate batch run (960 samples) in 1 hr 45 min 
b Based on an 8 hr day and includes sample preparation time 
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